Japanese Journal of Clinical Oncology 31:25-29 (2001)
© 2001 Foundation for Promotion of Cancer Research
Intravenous 5-Fluorouracil Versus Oral Doxifluridine as Preoperative Concurrent Chemoradiation for Locally Advanced Rectal Cancer: Prospective Randomized Trials
Departments of 1Surgery, 2Radiation Oncology and 3Medical Oncology, Yonsei University College of Medicine, Seoul, Korea
Background: Preoperative radiation treatment with concomitant intravenous infusion of 5-fluorouracil (5-FU) is known to be effective in shrinking and downstaging of tumors. However, chemotherapy has often been limited by its toxicity and poor patient compliance. Oral 5-FU is known to have several advantages over conventional intravenous 5-FU infusion such as lower toxicity and higher quality of life without compromising the efficacy of the treatment. The aim of this study was to compare intravenous 5-FU with oral doxifluridine with respect to tumor response, toxicity and quality of life.
Methods: Twenty-eight patients with rectal cancer, staged as over T3N1 or T4 by transrectal ultrasonography between July 1997 and December 1998, were included in this study. Intravenous 5-FU (450 mg/m2) and leucovorin (20 mg/m2) were given for five consecutive days during the first and fifth weeks of radiation therapy (50.4 Gy) (n = 14). Oral doxifluridine (700 mg/m2/day) and leucovorin (20 mg/m2) were given daily during radiation treatment (n = 14). Quality of life was scored according to 22 activity items (good, >77; fair, >58; poor, <57). Surgical resection was performed 4 weeks after completion of concurrent chemoradiation treatment. Tumor response was classified into CR (complete remission), PR (partial response; 50% diminution of tumor volume or downstaging ) and NR (no response).
Results: Tumor response was CR 3/14 (21.4%), PR 7/14 (50%) and NR 4/14 (28.6%) in the IV arm versus CR 2/14 (14.2%), PR 6/14 (42.9%) and NR 6/14 (42.9%) in the Oral arm (p = 0.16, 0.23, 0.24), respectively. The quality of life was poor (36.4% versus 33.3%), fair and good (63.6% versus 66.7%) between the IV arm and Oral arm, respectively. Gastrointestinal toxicity was 2/14 (14.3%) in the IV arm versus 5/14 (35.7%) in the Oral arm, respectively. Stomatitis was only observed in the IV arm (1/14, 7.1%). Hematological toxicity was 3/14 (21.4%) in the IV arm versus 4/14 (28.5%) in the Oral arm, respectively. Systemic recurrence during the follow-up periods were 1/14 (7.1%) in the IV arm and 2/14 (14.3%) in the Oral arm, respectively (p = 0.307). One local recurrence was observed in the Oral arm.
Conclusion: Even though the results were not entirely reliable owing to the small number of patients enrolled, oral doxifluridine-based chemotherapy as preoperative chemoradiation for advanced rectal cancer did not show any significant advantages over intravenous infusion.
+ For reprints and all correspondence: Nam Kyu Kim, Department of Surgery, Yonsei University College of Medicine, Seodamun-Gu, Shinchon-dong 134, CPO 8044, Seoul, Korea. E-mail: namkyuk@yumc.yonsei.ac.kr
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A Hartley, K F Ho, C McConkey, and J I Geh Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials Br. J. Radiol., October 1, 2005; 78(934): 934 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Rich, R. C. Shepard, and S. T. Mosley Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy J. Clin. Oncol., June 1, 2004; 22(11): 2214 - 2232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-J. Kim, J. S. Lim, Y. T. Oh, J. H. Kim, J.-J. Chung, S. H. Joo, N. K. Kim, K. Y. Lee, W. H. Kim, and K. W. Kim Preoperative MRI of Rectal Cancer With and Without Rectal Water Filling: An Intraindividual Comparison Am. J. Roentgenol., June 1, 2004; 182(6): 1469 - 1476. [Abstract] [Full Text] [PDF]
|
|